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Ole e 15 and its human counterpart 
-PPIA- chimeras reveal an 
heterogeneous IgE response in 
olive pollen allergic patients
Pablo San Segundo-Acosta1, Carmen Oeo-Santos1, Ana Navas2, Aurora Jurado2, 
Mayte Villalba1,4 & Rodrigo Barderas3,4*
Olive pollen is a major cause of immunoglobulin E (IgE)-mediated allergy in Mediterranean countries. 
It is expected to become a worldwide leading allergenic source because olive cultivation is increasing 
in many countries. Ole e 15 belongs to the cyclophilin pan-allergen family, which includes highly cross-
reactive allergens from non-related plant, animal and mold species. Here, the amino acid differences 
between Ole e 15 and its weak cross-reactive human homolog PPIA were grafted onto Ole e 15 to 
assess the contribution of specific surface areas to the IgE-binding. Eight Ole e 15-PPIA chimeras 
were produced in E. coli, purified and tested with 20 sera from Ole e 15-sensitized patients with olive 
pollen allergy by ELISA experiments. The contribution of linear epitopes was analyzed using twelve 
overlapping peptides spanning the entire Ole e 15 sequence. All the patients displayed a diverse 
reduction of the IgE-reactivity to the chimeras, revealing a highly polyclonal and patient-specific 
response to Ole e 15. IgE-epitopes are distributed across the entire Ole e 15 surface. Two main surface 
areas containing relevant conformational epitopes have been characterized. This is the first study to 
identify important IgE-binding regions on the surface of an allergenic cyclophilin.
Allergy is an immunoglobulin E (IgE)-mediated hypersensitivity which has become an important health prob-
lem in industrialized countries, affecting around 30% of their population. House dust mites and grass pollen are 
the most important aeroallergen sources1,2. However, in some regions, a higher prevalence of sensitization to 
specific local sources can be reached. Cultivated olive tree (Olea europaea ssp. europaea var. europaea) pollen is 
one of the main causes of pollinosis in the Mediterranean basin, being the main sensitizer in those areas where it 
is extensively cultivated3. Moreover, due to the continuous promotion of the Mediterranean diet, there is a rising 
demand for oil and olive fruit production worldwide, which will highly increase the number of olive trees and as 
a consequence, the number of allergic patients to this pollen4. To date, a total of fifteen olive allergens (Ole e 1 to 
15) have been identified5–7. Besides, an extensive proteomic profiling of olive pollen has been recently reported, 
making this important allergenic source one of the best characterized8.
About 13% of the olive pollen allergic patients sera present IgE against Ole e 15, an allergen belonging to 
the group of cyclophilins. These proteins normally exhibit peptidyl-prolyl cis-trans isomerase activity and are 
part of the protein superfamily of immunophilins9,10. Due to their essential role in protein folding, cyclophil-
ins are present in the cells of all organisms, and have been described as allergens in animals11, molds12–14 and 
plants15–17. Importantly, the amino acid sequence similarity among cyclophilins from unrelated species is high, 
and they could be considered pan-allergens due to their wide range of cross-reactivity13. Allergenic mold cyclo-
philins Mala s 6, Asp f 11 and Asp f 27 from Malassezia sympodialis and Aspergillus fumigatus, are major aller-
gens whose structure and immunological properties have been extensively studied, showing in vitro and in vivo 
cross-reactivity between them and also with their human homologs peptidyl-prolyl cis-trans isomerases A (PPIA) 
and B (PPIB)13,18,19. Ole e 15, as well as other plant pollen allergenic cyclophilins, like Bet v 7 from birch and Cat 
r 1 from periwinkle, belong to the subgroup of divergent cyclophilins, which present a conserved Glu83 residue, 
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two invariable cysteines and an additional stretch of seven amino acids with the consensus sequence XXGKXLH 
called divergent loop20. These allergens have also been shown to cross react with cyclophilins from plants8,17,21, 
animals (including human)8 and molds17,21.
The availability of structural information is essential to understand the cross-reactivity among different aller-
gens, determine the nature and location of their IgE-binding epitopes and use this information to design safer 
allergen-specific immunotherapy strategies22,23. Multiple human, parasite and mold cyclophilins structures have 
been reported since the first PPIA crystal structure was determined24,25. Moreover, the structure of wheat, orange 
tree and periwinkle cyclophilins have been recently reported17,26,27, revealing important information about the 
distribution and accessibility of amino acids across the protein surface, and the regulatory function of specific 
structural elements, such as the divergent loop.
IgE-binding epitopes of most aeroallergens are mainly conformational and strongly dependent on the native 
allergen conformation28–31. This makes the analysis of epitopes a challenge, and only a few conformational 
IgE epitopes have been structurally solved using nuclear magnetic resonance (NMR) or X-ray crystallogra-
phy32–34. Nevertheless, there are other strategies to identify specific IgE-binding surface areas, such as the use of 
random-peptide libraries mimicking real epitopes23, the design of point amino acid mutations to generate hypoal-
lergenic variants35, epitope grafting36 and protein engineering to create chimeric proteins of the allergen and 
homologous proteins37,38. Although three main linear B-cell epitopes responsible for the cross-reactivity between 
mold cyclophilins and PPIA have been predicted by in silico analysis39, there is no experimental information 
available about the relevant epitopes of these allergens. Here, we aimed to identify the contribution of specific 
areas of Ole e 15 to the IgE-binding. After in vitro assessment of Ole e 15 and PPIA cross-reactivity, and in silico 
structure comparison and calculation of solvent-accessible surface areas, eight chimeras carrying specific regions 
from PPIA were designed using Ole e 15 as scaffold. Their IgE-binding capacity was assessed by means of ELISA 
and inhibition ELISA experiments and thus, relevant IgE-binding regions of Ole e 15 were identified.
Results
In-vitro Ole e 15-PPIA IgE cross-reactivity analysis and design of Ole e 15-PPIA chimeras. Six 
sera from olive pollen allergic patients reaching OD492nm values higher than 0.4 when measuring IgE-binding to 
Ole e 15 by ELISA were tested with PPIA (Supplementary Fig. S1). Only serum 10 an 12 reached positive but low 
OD492nm values when they were ten-fold diluted (Supplementary Fig. S1a). Inhibition IgE ELISA with serum 12 
(Supplementary Fig. S1b) confirmed the previous results, with PPIA reaching inhibition values from 28% to 58% 
at concentrations at which Ole e 15 reached complete inhibition (4 μg/mL to 400 μg/mL).
To find an explanation for this low-degree of IgE cross-reactivity in spite of the high sequence identity shared, 
the amino acid sequences and 3D-structures of Ole e 15 and PPIA were compared to identify their main differ-
ences (Figs 1 and 2, and Supplementary Fig. S2). Three surface patches comprising the amino acid stretches with 
the majority of amino acid differences between both molecules were identified: Patch 1 (Ole e 15 stretch E43 to 
A59: divergent loop and surrounding residues), Patch 2 (Ole e 15 stretch M1 to A26: N-terminal β-strands β1 
and β2, and surrounding residues; and stretch Q138 to S172: C-terminal β-strand β8, α-helix α2 and the con-
necting loop), and Patch 3 (Ole e 15 stretch A76 to G101: region connecting β-strand β4 to β5). A fourth patch 
corresponding to the most conserved surface region, including the active site, was also found (Patch 4, Ole e 15 
stretch H61 to T75 and M107 to V134: β-strands β3, β4 and β7, and the loops connecting β-strands β3 to β4, β6 
to β7, and β7 to β8). The main exposed amino acids of each patch (relative value to the isolated individual amino 
acid SASA higher than 25%) are described in Supplementary Fig. S2. The calculated Ole e 15 SASA per residue 
revealed a total SASA value of 14282.87 Å2, with values of 1343.81 (9.4%), 3222.82 (22.6%), 2219.88 (15.85%) and 
2472.77 Å2 (17.3%) for the amino acid stretches included in Patches 1, 2, 3 and 4, respectively (Supplementary 
Table S1). Based on this information, nine protein chimeras were designed as described in the Material and 
Methods section.
Biochemical characterization of the recombinant proteins. Ole e 15, PPIA and all protein chimeras 
were successfully expressed and purified from the soluble fractions of E. coli lysates (Fig. 3A,B), except the chi-
mera lacking the Ole e 15 divergent loop (Chimera 3), which was expressed in inclusion bodies and could not be 
purified as a folded protein. Under non-reducing conditions, the purified proteins ran as two very close bands 
(Fig. 3B), as it has also been described for other cyclophilins19,26. CD spectroscopy was used to confirm a simi-
lar folding and the preservation of the structural integrity among Ole e 15, PPIA and the chimeras. All of them 
showed almost identical spectra, with barely observed changes at the secondary structure elements when spectra 
deconvolutions were performed (Fig. 3C,D).
The structure integrity of the recombinant proteins was further confirmed by ELISA experiments with an 
Ole e 15-specific pAb (Supplementary Fig. S3). ELISA experiments showed that all chimeras displayed a higher 
IgG-binding capacity than PPIA, with all of them, except Chimera 4, reaching OD492nm values highly similar to 
Ole e 15 (Supplementary Fig. S3a). These results were further confirmed by inhibition ELISA. All protein chime-
ras, except Chimera 4, reached inhibition values similar to Ole e 15 (Supplementary Fig. S3b).
Serum IgE-recognition patterns to Ole e 15 are highly diverse among olive pollen allergic patients. 
The IgE-binding capacity of Ole e 15, PPIA and the protein chimeras was assessed by ELISA (Fig. 4 and 
Supplementary Tables S2 and S3). Specific IgE-binding to Ole e 15 could be detected for the 20 used serum 
samples, whereas bound IgEs to PPIA could only be detected in the serum of two patients (Serum 10 and 12). 
Statistical analysis revealed a significant loss of IgE-recognition between Ole e 15, the protein chimeras and PPIA 
(Friedman test p-value lower than 0.001, mean OD for PPIA 0.05, mean ODs for protein chimeras 0.12–0.34, 
Supplementary Table S2). Significant differences between Ole e 15 and Chimera 1 (Dunn’s test p-value lower than 
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0.05), and Chimeras 8, 9, 4, 15 and 17 (Dunn’s test p-value lower than 0.001), but not significant when comparing 
to Chimeras 5 y 7 (Dunn’s test p-value higher than 0.05), were observed (Fig. 4).
Next, the different IgE-recognition profiles of each patient were examined. At least six different groups 
of patients could be distinguished according to their IgE recognition patterns (Supplementary Table S3). 
Importantly, all patients showed a decrease in the IgE-recognition capacity to protein chimeras compared to Ole 
e 15. The highest loss of IgE-recognition was mainly caused by the grafted regions on Chimera 4, and Chimeras 
15 and 17 (Patterns 1, 2 and 4, 13 patients, 65%). Interestingly, some patients (Pattern 3, 3 patients, 15%) showed 
a higher loss against Chimeras 8 and 9, whose grafted regions correspond only to the C-terminal region of Patch 
2. Other patients (Pattern 6, 2 patients, 10%) did not show a loss of IgE-recognition as high as other patients.
The loss of Ole e 15-specific IgE-binding to the grafted PPIA regions on the protein chimeras 
is confirmed by inhibition ELISA. The specific loss of IgE-binding capacity by the protein chimeras was 
further confirmed by inhibition ELISA experiments, in which Ole e 15 was coated and the chimeras and PPIA 
were used as inhibitors in the liquid phase. Results obtained from serum 6 and 11, for which inhibition experi-
ments using all chimeras were performed, are shown in Fig. 5. Further results were obtained for different serum 
samples with representative chimeras (Supplementary Fig. S4). In all cases Ole e 15 reached inhibition values 
near 95–100% at 5 μg/mL, whereas values for protein chimeras were variable and serum specific (Fig. 5A and 
Supplementary Fig. S4), ranging from 11% to 90%. The maximum inhibition value reached by PPIA was 25% 
(serum 11). The obtained OD values by ELISA with serum 6 and 11 (Fig. 5B) were compared to the inhibition 
values. A significant (p-values lower than 0.05) and high correlation (Spearman ρ values of 0.85 and 0.78, respec-
tively) was found (Fig. 5C).
Assessment of the IgG- and IgE-binding capacity of Ole e 15-derived peptides. Finally, to analyze 
the IgG- and IgE-binding to linear amino acid stretches on the surface of Ole e 15, thirteen overlapping pep-
tides covering the entire Ole e 15 sequence were produced at the C-terminal end of 6 × His-HaloTag constructs 
(Supplementary Fig. S5). Linear epitope mapping of the Ole e 15-specific pAb was performed by ELISA using 
immobilized peptides. Regions covered by peptides 6, 7, 8 and 9 (Patch 3 and near residues), and also 12 and 13 
(Patch 2, C-terminal region), were the most IgG-immunoreactive (Supplementary Fig. S6a). The IgE-binding 
capacity of peptides corresponding to the amino acid sequences of Patch 1 (Peptides 4 and 5), Patch 2 (Peptides 
1, 2, 12 and 13) and Patch 3 (Peptides 7 and 8) was assessed by inhibition ELISA with four representative serum 
Figure 1. Structure comparison between Ole e 15 and human PPIA. (A) Modeled molecular surface of Ole e 
15 (left). Light and dark gray colors indicate different and conserved amino acids between Ole e 15 and PPIA, 
respectively. The isolated surfaces of different (middle) and conserved (right) amino acids are also shown. 
(B) Modeled molecular surface pairs of Ole e 15 (left) and PPIA (right) for structure comparison. Three 
patches (Patch 1, 2 and 3) containing most of the different amino acids between both molecules, and a fourth 
patch (Patch 4) with conserved amino acids were found. All patches are framed. Light and dark gray colors 
indicate different and conserved amino acids between Ole e 15 and PPIA, respectively. (A,B) All 3D-models 
were visualized using PyMOL 2.3 (https://pymol.org/2/). (C) Topological diagram showing the secondary 
elements of the predicted structure of Ole e 15. Patch 1 comprises the amino acid stretch E43 to A59, including 
the divergent loop; Patch 2 comprises the N-terminal M1 to A26, and the C-terminal Q138 to S172; Patch 
3 comprises A76 to G101; and Patch 4 comprises H61 to T75 and M107 to V134. Gray arrow, β-strand; red 
cylinder, α-helix; blue straight lines, β-turns and random coil structures.
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Figure 2. Modeled molecular surface and sequence and comparison between Ole e 15, PPIA and Ole e 15-
PPIA chimeras. (A) Front and back (turned 180° on the vertical axis) modeled surfaces of Ole e 15, PPIA 
and chimeric Ole e 15-PPIA proteins. Grafted amino acids on the chimeras are colored. All 3D-models were 
visualized using PyMOL 2.3 (https://pymol.org/2/). (B) Amino acid sequence alignment of Ole e 15, PPIA and 
the chimeras. Amino acid differences between Ole e 15 and PPIA are shaded in gray. Amino acid differences 
with a change in the SASA value higher than 30 Å2 or higher than 10 Å2 but with changes in the amino acid 
charge state are shown in bold. PPIA amino acids grafted on the chimeras are indicated and framed with the 
same color as represented in (A). (*), fully conserved residues; (:), amino acids with groups of strongly similar 
properties; (.), amino acids with groups of weakly similar properties.
5Scientific RepoRtS |         (2019) 9:15027  | https://doi.org/10.1038/s41598-019-51005-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
samples (Supplementary Fig. S6b). Little or no IgE-inhibition was achieved by the peptides, except for Peptides 4 
and 5, which reached 63.1% inhibition of the serum 3 IgE-reactivity to immobilized Ole e 15.
Collectively, these results confirmed that most of the Ole e 15 IgE epitopes are non-linear conformational 
epitopes.
Figure 3. Biochemical characterization of Ole e 15-PPIA chimeras. (A) Coomassie Blue staining of 1 μg of the 
purified chimeras after 15% SDS-PAGE under reducing conditions. (B) Analysis of the purification process 
of Chimeras 1 and 7 by Coomassie Blue staining after 15% SDS-PAGE of fractions obtained from different 
purification steps. SF, bacterial soluble lysis fraction; NR, not retained proteins; W5, fifth Ni-NTA agarose wash; 
E, eluted protein (1 μg, not reduced). (C) Circular dichroism spectra of Ole e 15, PPIA and the chimeras. (D) 
Bar-graph showing percentage values of each secondary structure elements after spectra deconvolution using 
the CDNN software.
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Discussion
In this study, we aimed at identifying relevant IgE-binding regions to Ole e 15 by grafting amino acids from spe-
cific surface areas of human PPIA, after confirming the lower PPIA capacity of binding Ole e 15 specific-IgEs from 
olive pollen allergic patients. Then, we assessed the potential loss of IgE-binding of the resulting Ole e 15-PPIA 
chimeras. Although similar approaches have already been used with other allergens like Bet v 137,40, Mal d 136, 
Ole e 138, Ves v 541 and Pen a 142, we are the first to report information on relevant IgE-binding surface areas of an 
allergenic plant cyclophilin.
The sequence and surface comparison between PPIA and Ole e 15 revealed that the amino acid changes 
between both molecules, although only comprising 21.5% and 24.6% of the Ole e 15 and PPIA total SASA, respec-
tively, were distributed over the entire surface (Fig. 1A). Therefore, these changes could be responsible for the 
loss of the IgE-binding capacity of several surface areas which in Ole e 15 correspond to potential main epitopes, 
explaining the low seroreactivity of PPIA (Supplementary Fig. S1).
A typical conformational IgG or IgE protein epitope comprises surface areas of around 700~1000 Å2, as 
revealed by X-ray crystallography studies on antibody-antigen complexes34,43,44. Three main Ole e 15 surface 
patches were identified with areas wide enough to be epitopes, and containing most of the amino acid differences 
between both molecules (Fig. 1B,C, Supplementary Fig. S2 and Supplementary Table S1). Then, PPIA amino 
acids were grafted onto these patches, generating eight chimeric proteins, to assess the contribution of the sub-
stituted regions to the IgE-binding to Ole e 15. An essential prerequisite to obtain reliable information from the 
grafted areas is the conservation of an equivalent protein folding. Thus, CD spectroscopy was used to analyze the 
secondary structure of Ole e 15, PPIA and chimeric proteins. A highly-similar spectra and an almost equivalent 
proportion of secondary structure elements were found (Fig. 3). The conservation of the cyclophilin folding 
was also confirmed by ELISA and inhibition ELISA experiments with an Ole e 15-specific pAb (Supplementary 
Fig. S3). All proteins showed IgG-binding capacity, revealing common epitopes between Ole e 15 and PPIA 
(Supplementary Fig. S3a). Moreover, all chimeras except Chimera 4 showed OD and inhibition values equivalent 
to those of Ole e 15 (Supplementary Fig. S3b). These results suggested that the mutated amino acids of Chimera 
4 were essential for the pAb-binding to at least one important epitope composed by amino acids between D75 to 
A110, as revealed by the pAb-linear epitope mapping (Supplementary Fig. S6a). The correct folding was further 
confirmed after SDS-PAGE under non-reducing conditions and Coomassie Blue staining, which showed that 
purified proteins ran as a lower band corresponding to the reduced state of the protein and a close upper band 
representing an oxidized form with an intramolecular disulfide bond (Fig. 3B). This bond, formed between C40 
and C168 residues, which are very close in the native structure, has been shown to be part of a 2-cysteine redox 
mechanism controlling enzyme activity19,26.
Among the three identified surface patches with most of the amino acid changes between Ole e 15 and PPIA, 
the Patch 2 covered the widest SASA (3222.82 Å2), contained three defined sequence stretches (N-terminal M1 to 
Figure 4. IgE-binding of Ole e 15, PPIA and Ole e 15-PPIA chimeras. (A) Scatter dot-plot representing the 
IgE-reactivity of the twenty patients to Ole e 15, PPIA and the chimeras assessed by ELISA. Results are shown 
as OD492nm values (arbitrary units). Horizontal bars represent the arithmetic mean. Vertical bars represent the 
standard error of the mean (±SEM, error bars for duplicates). The dashed line represents the cut-off level of IgE-
binding. *P < 0.05; ***P < 0.001, ns (not significant). (B) Visualization of the normalized results per patient in 
OD in (A) by hierarchical clustering analysis performed with MultiExperiment Viewer (MeV). Red, higher IgE 
levels. Green, low or nor IgE levels.
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A26, inner C-terminal Q138 to G155 and outer C-terminal G155 to S172 regions) and accumulated the highest 
number of amino acid changes between Ole e 15 and PPIA. Numerous studies describe that antibody-antigen 
interactions mainly depend on charged, polar or aromatic epitope residues with a high SASA38,45,46. Then, 
Figure 5. Immunological characterization of the IgE-response to Ole e 15, PPIA and Ole e 15-PPIA chimeras 
of two representative olive pollen allergic patients. (A) Bar graphs showing inhibition values of IgE-binding to 
immobilized Ole e 15 assesed by ELISA after serum preincubation with Ole e 15, PPIA or the Ole e 15-PPIA 
chimeras. (B) Bar graphs representing the mean OD492nm (±SD) values obtained by ELISA for the assessment of 
the IgE-reactivity of serum samples 6 and 11. The dashed line represents the cut-off level of IgE-binding. (C) Two-
tailed Spearman correlation analysis at 95% confidence interval between the obtained ELISA OD492nm values and 
the IgE-inhibition values at inhibitor concentrations of 0.5 μg/mL. Spearman ρ, Spearman correlation coefficient.
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assuming that a high change in the SASA value or a change in the charge state of amino acids would most prob-
ably alter the potential IgE-binding to each region, only PPIA amino acids meeting a set of criteria (see Materials 
and Methods section) were grafted onto Ole e 15 to create Chimeras 1, 5 and 7 (Table 1 and Fig. 2). Interestingly, 
all serum samples showed a loss of seroreactivity against these three chimeric proteins, confirming that the 
mutated amino acids, very close in the 3D-structure, were part of one or more conformational IgE-binding 
epitopes located on Patch 2 (Fig. 2 and Supplementary Table S2). The loss of IgE-reactivity against the three 
chimeras was similar for some patients (Pattern 1, Supplementary Table S3), but in other cases the loss against 
Chimera 1 was higher (Pattern 2 patients, Supplementary Table S3), suggesting a patient-specific IgE-repertoire 
against Patch 2. For Pattern 1 patients, all the mutated amino acids might similarly contribute to the IgE-binding 
to a common conformational epitope, whereas in the case of Pattern 2 patients, the N-terminal residues might be 
more relevant to the IgE-binding to that epitope or be part of a different one.
Mutations at the N- and C-terminal regions were combined in Chimeras 15 and 17 to further analyze their 
contribution to the IgE-recognition of Patch 2. Both chimeras displayed a higher loss of IgE-reactivity than 
Chimeras 1, 5 and 7, and for some patients that loss was complete. These results confirmed that the mutated 
amino acids were part of at least one relevant epitope located on Patch 2 and surrounding areas. Moreover, the 
contribution of the whole C-terminal Patch 2 region (Q138 to S172) to IgE-binding was further studied using 
Chimeras 8 and 9. For Pattern 2 and Pattern 6 patients, the loss of seroreactivity by Chimeras 8 and 9 was similar 
to that caused by Chimeras 5 and 7, suggesting that the amino acid mutations of Chimeras 5 and 7 were sufficient 
to provoke the loss of IgE-binding. On the other hand, for Pattern 1 or Pattern 3 patients, those amino acids muta-
tions were not sufficient, and the exclusive mutations of Chimeras 8 and 9 provoked a higher loss, which further 
supported the idea that these patients present a different IgE-repertoire against this region. Besides, the fact that 
Chimeras 8 and 9 showed a similar loss of IgE-reactivity by most patients indicated that the amino acid mutations 
of Chimera 8 were sufficient to lower IgE-binding.
For Chimera 4, seven amino acids were grafted from PPIA onto Ole e 15 to analyze the role of Patch 3 in 
IgE-binding (Table 1 and Fig. 2). Interestingly, most of the serum samples showed a reduced IgE-binding capacity 
to this chimera compared to Ole e 15, suggesting this region was part of a relevant epitope. The sequence belong-
ing to this patch, which contains the amino acids of the regulatory catalytic loop26, had the highest relative SASA 
per amino acid (Supplementary Table S1). Besides, five of the seven mutated amino acids in this region met the 
criteria on changes in the SASA value and charge state. Thus, the number and nature of these amino acid changes 
might explain why the IgE-reactivity of Chimera 4 was also the lowest of all the chimeras.
Several IgE-binding studies of Bet v 136,37, Der p 247,48 and other allergens49,50 have revealed that the 
allergen-specific IgE-repertoire can be very complex in terms of IgE-clonality, affinity and concentration. Besides, 
it is well-known that these parameters affect effector cell degranulation, which is only triggered in the presence 
of at least two IgE-clones binding non-overlapping epitopes on the allergen surface51. This is consistent with our 
results, where at least six different serum recognition patterns against the chimeric proteins could be identified 
and all patients lost IgE-recognition to a different extent when amino acids from Patch 2 and Patch 3, belonging 
to at least two different epitopes, were mutated. Interestingly, it has been proposed that every region of the solvent 
exposed surface of a protein can be potentially immunogenic and then, part of a B-cell epitope, although some 
epitopes are more recognized than others52,53. In fact, a recent study showed that 20 out of 64 Bet v 1-allergic 
patients tested presented IgEs against at least four well-defined regions on the Bet v 1 surface after they were 
grafted onto the homologous low IgE-binding allergen Api g 137.
Other two patches on the surface of Ole e 15 (Patch 1 and Patch 4, Fig. 1 and Supplementary Fig. S2) with 
sufficient areas to contain potential epitopes were identified. Regarding Patch 1, an Ole e 15 mutant lacking the 
Recombinant Ole e 15-PPIA* chimeras
Amino acid substitutions
Chimera 1a K5T, G13D, Q15E
Chimera 3b K48 to H54 deletion
Chimera 4c A76R, G77H, E83K, S88E, A91E, V96I, K97L
Chimera 5d V140K, K147E, Q151R, G155R
Chimera 7e G155R, P162K, S172E
Chimera 8f G155R, S156N, P162K, V163I, V164T, V165I, S172E
Chimera 9g Q138K, V140K, K147E, Q151R, G155R, S156N, P162K, V163I, V164T, V165I, S172E
Chimera 15h K5T, G13D, Q15E, V140K, K147E, Q151R, G155R
Chimera 17i K5T, G13D, Q15E, G155R, P162K, S172E
Table 1. Mutated amino acids in the chimeric proteins. *PPIA, human cyclophilin A (also known as CypA). 
aN-terminal Patch 2 (M1 to A26) mutations (only amino acids meeting the criteria on solvent exposure/charge 
state changes). bDeletion of the divergent loop (Patch 1). cWhole Patch 3 (A76 to G101) mutations (all different 
amino acids were grafted). dInner C-terminal Patch 2 (V140 to G155) mutations (only amino acids meeting the 
criteria). eOuter C-terminal Patch 2 region (G155 to S172) mutations (only amino acids meeting the criteria). 
fOuter C-terminal Patch 2 region mutations (all different amino acids were grafted). gWhole Patch 2 C-terminal 
region (Q138 to S172) mutations (all different amino acids were grafted). hN-terminal and inner C-terminal 
Patch 2 mutations (only amino acids meeting the criteria). iN-terminal and outer C-terminal Patch 2 mutations 
(only amino acids meeting the criteria).
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divergent loop amino acid sequence was designed (Table 1), but it could not be produced as a folded protein. 
However, in a previous study in which an equivalent Cat r 1 mutant could be produced, no loss of its IgE-binding 
capacity could be detected17. Here, after using two peptides containing the loop sequence and surrounding resi-
dues as solution inhibitors by ELISA, we only observed high inhibition values in one of the four serum samples 
tested (Supplementary Fig. S6b). Interestingly, this patient did not show a high reduction of the IgE-reactivity 
compared to other patients (recognition pattern 6), so Patch 1 residues might be part of a relevant IgE-binding 
region for some patients. Other peptides were also used to analyze the potential contribution of sequential amino 
acid stretches in Patch 2 and Patch 3, but no important inhibition values were reached, further suggesting that the 
amino acids of these regions were part of conformational epitopes. Nevertheless, the use of peptides gives limited 
information on the IgE-binding capacity of the represented regions, as they do not usually display the real topo-
logical structure of the native protein surface31,53. Thus, the contribution of sequential stretches to the IgE-binding 
to these regions cannot be fully discarded, and further studies should be performed to determine whether Patch 1 
is a region containing amino acids belonging to a main epitope for olive pollen allergic patients.
The IgE-mediated cross-reactivity between allergens sharing high sequence identity with their human 
counterparts has been described for proteins like the pan-allergens profilins or the fungal allergens manganese 
superoxide dismutase, acidic ribosomal P2 protein and thioredoxin54. This cross-reactivity has also been demon-
strated in vitro and in vivo between the fungal cyclophilins Mala s 6 and Asp f 11 and PPIA and PPIB, and seem 
to be especially relevant in patients suffering from allergic bronchopulmonary aspergillosis19. Here, only two 
patients showed IgE-reactivity against PPIA by ELISA, and very low inhibition values were reached using PPIA 
as inhibitor, revealing a weak in vitro cross-reactivity between Ole e 15 and PPIA among olive pollen allergic 
patients. Interestingly, the protein regions predicted in silico as the main epitopes accounting for this interspecies 
cross-reactivity belong to the active site region39. In Ole e 15, these regions are part of the Patch 4. Hence, the weak 
Ole e 15-PPIA cross-reactivity might be explained by the presence of IgE antibodies in low levels or with low 
affinity or clonality against this region. Nevertheless, it has been proven that the presence in the IgE-repertoire of 
only two non-overlapping allergen-specific antibodies, one with high affinity and another with very low affinity, is 
sufficient to produce functional high affinity IgE receptor (FcɛRI)/IgE/allergen complexes on the surface of effec-
tor cells51. Then, this in vitro cross reactivity, although weak, might be clinically relevant, and further studies to 
address it by in vivo experiments and to confirm the role of Patch 4 as an IgE-binding region should be performed.
The identification of relevant IgE epitopes on the surface of allergens gives fundamental information about the 
generation of the IgE-repertoire by allergic patients and allows for a better prediction of cross-reactivity between 
allergens by using epitope sequence similarity rather than whole allergen sequence53. Besides, it is important for 
the design of hypoallergenic variants with low capacity of effector cell activation for allergen-specific immuno-
therapy31,55. Here, Chimeras 15, 17 and 4 displayed a very reduced IgE-binding capacity compared to Ole e 15 and 
their suitability as hypoallergenic variants should be addressed by basophil activation tests and T-cell reactivity 
experiments.
Conclusion
In summary, this study shows that there is a weak but relevant in vitro cross-reactivity between PPIA and Ole e 
15 and that the Ole e 15-specific IgE-response is highly polyclonal and patient specific. Two main IgE-binding 
regions on the surface of Ole e 15 have been identified after the immunological characterization of eight Ole e 
15-PPIA chimeras displaying lower IgE-binding capacities than Ole e 15. Thus, we demonstrate that grafting 
specific areas from a low IgE-binding homolog like PPIA is useful to identify the main IgE-binding sites of an 
allergen.
Materials and Methods
Patients and control subjects. Twenty sera from olive pollen allergic patients obtained by standard oper-
ating procedures from two different Spanish populations (Córdoba and Madrid) were used according to their 
positive olive pollen skin prick test (SPT), presence of IgE antibodies against olive pollen extract as measured by 
ImmunoCAP 250 (Thermo Scientific, Uppsala, Sweden) or ELISA, and presence of specific IgE against recombi-
nant Ole e 15 (Ole e 15) as determined by ELISA. SPT was performed according to standard procedures. A wheal 
diameter lower than 3 mm was considered negative. Values higher than 0.35 kU/L by ImmunoCAP, or higher 
than 0.1 optical density at 492 nm (OD492 nm, arbitrary units) by ELISA were considered positive. All patients 
included in this study reported an immediate IgE-mediated allergic reaction and a positive SPT with olive pollen.
The Institutional Ethical Review Boards of the Complutense University of Madrid, ISCIII (CEI PI 49) and 
Reina Sofia University Hospital (ref. 3033) approved this study involving allergic patients. All samples were han-
dled anonymously according to the ethical and legal guidelines of the Complutense University of Madrid and 
Reina Sofia University Hospital after approval of the Ethical Review Boards of these institutions. All subjects in 
the study gave their written informed consent to participate and all experiments were performed in accordance 
with relevant guidelines and regulations. All patients presented asthma or rhinoconjunctivitis. Detailed demo-
graphic and clinical information of the olive pollen allergic patients is depicted in Supplementary Table S4. Three 
non-atopic subjects were used as controls.
Ole e 15 and PPIA structure comparison and design of Ole e 15-PPIA chimeras. A three-dimensional 
(3D)-model of Ole e 15 was obtained with the ExPASy homology-modelling server Swiss-Model56 using the 
NMR solution ligand-free structure of the allergenic plant cyclophilin Cat r 1 as template (PDB: 2mc9, 86% 
sequence identity and 92% similarity with Ole e 15). For PPIA, the NMR solution structure (PDB: 1OCA) was 
used. Three-dimensional structures were visualized using PyMOL 2.3 (Schrödinger, LCC, New York) and amino 
acid sequences were aligned using Clustal Omega57. Sequence and structure comparison allowed for the identifi-
cation of four main surface patches gathering most of the different (Patches 1, 2 and 3) or the conserved (Patch 4) 
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amino acids between Ole e 15 and PPIA (see Figs 1 and 2, and Supplementary Fig. S2). Then, solvent-accessible 
surface areas (SASAs) per residue from both molecules were calculated using Parameter OPtimized Surfaces 
(POPS)58, and the SASAs of the changing amino acids were compared. All protein chimeras were created by 
grafting amino acids from PPIA onto Ole e 15. Amino acid pairs belonging to Patch 2, and meeting the following 
criteria, were considered for grafting in the case of Chimeras 1, 5 and 7: a change of SASA value higher than 30 
Å2, or a change of SASA value higher than 10 Å2 but with a change in the potential charge state of the amino acid 
(Table 1, Fig. 2, and Supplementary Table S1). Thus, Chimera 1 was designed by mutating three amino acids in the 
Patch 2 N-terminal region (M1 to A26), and Chimeras 5 and 7, by mutating four amino acids in the Patch 2 inner 
C-terminal region (Q138 to G155) and three amino acids in the Patch 2 outer C -terminal region (G155 to S172), 
respectively. Chimeras 15 and 17 were designed as a combination of the mutations in Chimeras 1 and 5, and 
Chimeras 1 and 7. For the rest of the chimeras, the above criteria were not applied. Chimera 4 was designed by 
changing all the corresponding amino acids in Patch 3; Chimera 8, all amino acids in the Patch 2 inner C-terminal 
region; and Chimera 9, all amino acids in the Patch 2 (inner C-terminal and outer C-terminal regions, Q138 to 
S172). A deletion mutant (Chimera 3) was also designed by removing the amino acids of the Ole e 15 divergent 
loop (K48 to H54 in Patch 1). All amino acid changes are summarized in Table 1.
Cloning, expression and purification of recombinant proteins. Overlapping oligonucleotides 
were designed to generate the chimera-coding DNA fragments by PCR amplification. pET28a-derived expres-
sion vectors containing Ole e 15 and PPIA-coding sequences were used as templates. The obtained fragments 
were later assembled into expression vectors using NEBuilder HiFi DNA Assembly Mix (New England Biolabs, 
USA). Thirteen peptides of twenty four amino acids in length and with twelve amino acid overlaps covering 
the entire Ole e 15 amino acid sequence were also designed (Supplementary Fig. S5). Each DNA insert with the 
peptide coding sequence was generated by PCR-amplification of attB-site containing oligonucleotides overlap-
ping by twenty nucleotides. Then, each insert was simultaneously cloned into pDONR221 and pDEST-HisHALO 
as donor and destination (expression) vectors, respectively, using single-step combined BP/LR Gateway reac-
tions (Thermo Fisher Scientific, Waltham, MA, US)59. Oligonucleotides were purchased from Sigma-Aldrich 
(St.Louis, MO, US) (Supplementary Table S5). A random peptide (control peptide) with the sequence 
HGRIKQVCTKKQASSGVMLGDPNS was used as control.
Ole e 15, PPIA, protein chimeras and HaloTag-fused peptides were recombinantly produced in E. coli as 
N-terminal His6-tagged proteins. The pET28a/pDEST-HisHALO expression constructs were used to transform 
BL21 (DE3) E. coli cells. LB cultures of 10 mL with 30 μg/mL kanamycin containing the transformed cells were 
grown overnight and then, diluted ten times and grown until OD600nm reached 0.7. Finally, protein expression 
was induced with 0.4 mM isopropyl thio-β-D-thiogalactoside (IPTG) and grown at 37 °C 230 rpm four hours (for 
HaloTag-fused peptides 1 to 11, 13 and control peptide), 30 °C 230 rpm for sixteen hours (for Ole e 15, PPIA and 
Chimeras 1, 5, 7, 8, 15, 17), or at 16 °C 230 rpm for forty eight hours (for Chimeras 4 and 9, and HaloTag-fused 
peptide 12). Then, the cultures were centrifuged at 6,000 × g for twenty minutes at 4 °C. Proteins were purified 
by gravity-flow chromatography from the soluble fraction of cell lysates using Ni-NTA agarose (Qiagen, Hilden, 
Germany) following the manufacturer instructions with minor modifications. Briefly, cell pellets corresponding 
to 250 or 500 mL E. coli cultures were resuspended in 10 mL lysis buffer (300 mM NaCl, 1 mM PMSF, 50 mM 
phosphate buffer pH 7.0), distributed in 1 mL aliquots and disrupted by five cycles of subsequent freezing in liq-
uid N2 for forty seconds and thawing at 42 °C in a water bath. Then, soluble fractions obtained by centrifugation 
at 6,000 × g for twenty minutes at 4 °C were incubated sixteen hours at 4 °C in a 15 mL conical centrifuge tubes 
with 500 μL Ni-NTA agarose previously pre-incubated three times with 5 mL lysis buffer for two minutes. After 
that, Ni-NTA agarose was washed five times for ten minutes at 4 °C with 5 mL wash buffer (10 mM imidazole, 
300 mM NaCl, 50 mM phosphate buffer pH 7.0), recovering each time the resin by centrifugation at 4,000 × g for 
ten minutes at 4 °C. Proteins were then eluted with 5 mL elution buffer (250 mM imidazole, 300 mM NaCl, 50 mM 
phosphate buffer pH 7.0) for twenty minutes at 4 °C on rotation. To avoid the presence of traces of Ni-NTA aga-
rose in the eluted fractions, a final centrifugation step was performed at 12,000 × g for five minutes at 4 °C. Finally, 
purified proteins were desalted onto PD10 desalting columns (GE Healthcare, Chicago, IL, US) with 150 mM 
ammonium bicarbonate, quantified, aliquoted, lyophilized and stored at −20 °C until use.
Analytical methods, antibodies and physicochemical analysis. Purity of the recombinant proteins 
was analyzed by 15% SDS-PAGE and subsequent staining with Coomassie Blue R-250 (Sigma-Aldrich, St.Louis, 
MO, US). Theoretical molecular mass calculations were performed using unstained protein biomarkers SM0431 
(Fermentas, Waltham, MA, US).
The rabbit polyclonal antiserum against Ole e 15 (Ole e 15-specific pAb) was previously obtained8.
Circular dichroism (CD) spectra of Ole e 15, PPIA and protein chimeras in 20 mM phosphate buffer pH 
7.0, at 0.2 mg/mL and 20 °C were recorded in the far-UV (190–260 nm) on a J-715 spectropolarimeter (JASCO, 
Japan Spectroscopic Co., Tokyo, Japan) using a 0.1 cm optical-path quartz cuvette. The deconvolution of the 
obtained spectra was performed using the CDNN software (thirty three reference net spectra, complex CD spec-
trum). Finally, the obtained far UV spectra were baseline-subtracted and represented as mean residue molecular 
ellipticity.
Protein concentration of purified Ole e 15, PPIA and protein chimeras was calculated after amino acid anal-
ysis of 14 μg purified proteins in duplicates with a BioChrom 30 Amino Acid analyzer (Harvard Bioscience, Inc., 
Holliston, MA, US). Protein concentration of the purified HaloTag-fused peptides was calculated by measuring 
the absorbance at 280 nm using a DU-7 spectrometer (Beckman, Barcelona, Spain) after theoretical extinction 
coefficient calculation with the ProtParam tool from ExPASy.
1 1Scientific RepoRtS |         (2019) 9:15027  | https://doi.org/10.1038/s41598-019-51005-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
IgE and Ole e 15-specific pAb ELISA experiments. To detect IgE-binding by ELISA, high-binding 
microplates (Costar, Corning, New York, US) were coated overnight at 4 °C with 50 μL/well of 10 μg/mL Ole e 
15, PPIA and protein chimeras in phosphate-buffered saline (PBS). After washing four times with 0.5% Tween 
20-PBS, non-specific binding sites were blocked at 37 °C one hour with 100 μL/well 3% skimmed milk 0.1% 
Tween-PBS (blocking buffer). Then, 50 μL/well sera ten-fold diluted in blocking buffer were incubated in dupli-
cate at 37 °C for two hours. After washing, bound IgEs were detected by incubating 50 μL/well 103-fold blocking 
buffer-diluted horseradish-peroxidase-conjugated mouse anti-human IgE mAb (Southern Biotech, Birmingham, 
AL, US) one hour at 37 °C. Color was developed for thirty minutes with o-phenylenediamine chloride and 
H2O2 as substrates (Merck, Darmstadt, Germany), and the reaction was stopped with 1 N H2SO4. Absorbance 
was measured at 492 nm. Incubation with three sera from non-atopic individuals, and incubation with block-
ing buffer instead of serum (background), were used as controls of the assay. Normalized OD values (sample 
OD492nm-background) were considered positive when the cut-off absorbance value was higher than 0.1 (exceed-
ing always the mean background by 3 SDs). For Ole e 15-specific pAb-ELISAs, plates were coated with 100 μL/
well of 1 μg/mL proteins or 5 μg/mL fusion-peptides, in PBS. For Ole e 15, PPIA and protein chimeras titration 
curves, each well was incubated with 100 μL serial dilutions (from 104 to 3 × 104-fold) of Ole e 15-specific pAb in 
blocking buffer at 37 °C for one hour. To assess the recognition of the HaloTag fused-peptides, the antibody was 
2.5 × 103-fold diluted. Specific IgG-binding was detected using a horseradish peroxidase-labeled goat polyclonal 
antibody against rabbit IgG (Bio-Rad, Richmond, CA, USA).
Inhibition ELISAs. For all inhibition ELISAs, procedures like coating, blocking and color development were 
performed as described above. For IgE-inhibition with Ole e 15, PPIA and chimeras, diluted sera (seven point 
five to twenty five-fold) were preincubated in duplicate for two hours at room temperature with ten-fold serial 
dilutions, from 0.005 to 5 μg/mL, or alternatively, 0.001 to 1 μg/mL, of the inhibitor proteins. For IgE-inhibition 
with HaloTag-fused peptides, diluted sera (fifteen to twenty five-fold) were preincubated with each peptide at 
2 μM concentration.
Inhibition values were calculated with the following formula:
= − ×−Inhibition(%) (1 OD /OD ) 100inhibited non inhibited
Statistical analysis. The Friedman test and the Dunn’s post test (95% Confidence Interval (CI)) were per-
formed to analyze whether the reduction of the IgE-recognition capacity of each serum against protein chimeras 
and PPIA in comparison to Ole e 15, was significant. Moreover, the relationship between the OD492nm values 
obtained by ELISA and the inhibition experiments was analyzed using Spearman correlation (95% CI).
Data availability
The data are available as supplementary information.
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